Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Surface Oncology, Inc. SURF
$0.61
-$0 (-0.28%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
37340894.00000000
-
week52high
2.15
-
week52low
0.56
-
Revenue
30000000
-
P/E TTM
-1
-
Beta
1.68858100
-
EPS
-1.10000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 08 авг 2022 г. |
| BTIG | Buy | 18 мая 2021 г. | |
| HC Wainwright & Co. | Buy | 04 сент 2020 г. | |
| Wedbush | Outperform | 28 авг 2020 г. | |
| Baird | Outperform | 19 сент 2018 г. | |
| HC Wainwright & Co. | Buy | Buy | 03 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Adams Chandra | A | 30000 | 30000 | 01 ноя 2022 г. |
| Palombella Vito J. | D | 87212 | 4463 | 03 авг 2022 г. |
| FEES JESSICA | D | 111349 | 5980 | 03 авг 2022 г. |
| ROSS ROBERT W. | D | 99906 | 10594 | 03 авг 2022 г. |
| ONEILL ALISON | D | 63728 | 4463 | 03 авг 2022 г. |
| RATH HENRY C. | D | 32324 | 5676 | 03 авг 2022 г. |
| Brunn Carsten | A | 48000 | 48000 | 28 июн 2022 г. |
| Goater Jeff | A | 24000 | 24000 | 08 июн 2022 г. |
| GRAYZEL DAVID S. | A | 24000 | 24000 | 08 июн 2022 г. |
| Ibrahim Ramy | A | 24000 | 24000 | 08 июн 2022 г. |
Новостная лента
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
GlobeNewsWire
07 ноя 2022 г. в 08:00
Data further support SRF388 and SRF114 clinical development programs Data further support SRF388 and SRF114 clinical development programs
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
GlobeNewsWire
14 сент 2022 г. в 07:30
- New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition -
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
GlobeNewsWire
07 сент 2022 г. в 16:30
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.